Kim De Veirman

The gut microbiome in multiple myeloma: from disease evolution to therapeutic modulation

The therapeutic landscape of Multiple Myeloma (MM), the second most common haematological malignancy, has undergone a paradigm shift with the introduction of anti-CD38 targeting monoclonal antibodies, immunomodulatory drugs and B-cell maturation antigen (BCMA) targeting Chimeric...